[{"address1": "100 Overlook Center", "address2": "Suite 102", "city": "Princeton", "state": "NJ", "zip": "08540", "country": "United States", "phone": "609 375 2227", "website": "https://www.sonnetbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pankaj  Mohan Ph.D.", "age": 58, "title": "Founder, Chairman, CEO & President", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 538998, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John K. Cini Ph.D.", "age": 70, "title": "Chief Scientific Officer & Co-Founder", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 397750, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jay  Cross", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 389953, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donald J. Griffith CPA, CPA", "age": 74, "title": "Financial Controller & Director", "yearBorn": 1949, "fiscalYear": 2024, "totalPay": 90256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gael  Hedou Ph.D.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Dexter", "age": 68, "title": "Chief Technical Officer", "yearBorn": 1955, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard T. Kenney FACP, M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Manuel  Dafonseca", "title": "Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen J. McAndrew Ph.D.", "age": 69, "title": "Senior Vice President of Business Development", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 1.71, "open": 1.7, "dayLow": 1.7, "dayHigh": 1.93, "regularMarketPreviousClose": 1.71, "regularMarketOpen": 1.7, "regularMarketDayLow": 1.7, "regularMarketDayHigh": 1.93, "beta": 1.045, "forwardPE": -0.1223262, "volume": 310579, "regularMarketVolume": 310579, "averageVolume": 1487778, "averageVolume10days": 277690, "averageDailyVolume10Day": 277690, "bid": 1.36, "ask": 2.22, "bidSize": 200, "askSize": 200, "marketCap": 5503597, "fiftyTwoWeekLow": 1.41, "fiftyTwoWeekHigh": 18.72, "priceToSalesTrailing12Months": 98.48781, "fiftyDayAverage": 2.0644, "twoHundredDayAverage": 7.1264, "currency": "USD", "enterpriseValue": -2229971, "floatShares": 585988, "sharesOutstanding": 3007430, "sharesShort": 40115, "sharesShortPriorMonth": 66231, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0479, "heldPercentInsiders": 0.0138, "heldPercentInstitutions": 0.002, "shortRatio": 0.03, "shortPercentOfFloat": 0.048499998, "impliedSharesOutstanding": 3007430, "bookValue": 4.014, "priceToBook": 0.45590436, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -7985378, "trailingEps": -11.35, "forwardEps": -14.96, "lastSplitFactor": "1:8", "lastSplitDate": 1727654400, "enterpriseToRevenue": -39.906, "enterpriseToEbitda": 0.182, "52WeekChange": -0.84749997, "SandP52WeekChange": 0.23809385, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SONN", "underlyingSymbol": "SONN", "shortName": "Sonnet BioTherapeutics Holdings", "longName": "Sonnet BioTherapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1162305000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e0f4f091-b896-3bb3-bb50-c62febf22cab", "messageBoardId": "finmb_410378138", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.83, "targetHighPrice": 160.0, "targetLowPrice": 160.0, "targetMeanPrice": 160.0, "targetMedianPrice": 160.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 3554331, "totalCashPerShare": 5.207, "ebitda": -12263398, "totalDebt": 150186, "quickRatio": 1.31, "currentRatio": 1.649, "totalRevenue": 55881, "debtToEquity": 5.736, "revenuePerShare": 0.019, "returnOnAssets": -0.96928, "returnOnEquity": -2.64567, "grossProfits": -6325117, "freeCashflow": -9881685, "operatingCashflow": -9996666, "operatingMargins": -219.68546, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]